New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 26, 2013
06:45 EDTAMRNAmarin submits sNDA for Vascepa
Amarin Corporation announced that it has submitted a Supplemental New Drug Application, or sNDA, with the FDA seeking approval for the marketing and sale of Vascepa capsules for use as an adjunct to diet in the treatment of adult patients with high triglycerides with mixed dyslipidemia. Amarin expects to hear within 74 days from the FDA whether the sNDA submission has been accepted for review.
News For AMRN From The Last 14 Days
Check below for free stories on AMRN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for AMRN

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use